TAKE Solutions began as a software-services firm in 2000, but its identity was forged in the Life Sciences industry, where it spent two decades becoming India’s only publicly listed full-service Clinical Research Organization (CRO) - a company that helps drugmakers run clinical trials, navigate regulations, and monitor drug safety. After a series of enforced asset sales in 2022 and 2024 stripped away nearly all of that legacy business, the company renamed itself TAKE LIMITED and pivoted sharply toward a new thesis: using artificial intelligence to build digital health platforms and longevity-science ventures for India’s preventive-care market. The recurring thread across both eras is a self-described “domain-intensive, knowledge-centric” approach - combining deep regulatory and clinical know-how with technology, first to serve pharmaceutical companies and now to target consumers and healthcare providers directly.
Business segments
Two engines at opposite ends of the corporate lifecycle - a divested CRO powerhouse that once generated nearly all revenue, and a newly assembled portfolio of AI-driven digital health and longevity platforms that represent the company’s future.
1. Life Sciences CRO: the full-service drug-development engine that was sold
Under the Navitas Life Sciences brand, the company ran clinical trials, regulatory filings, and drug-safety monitoring for global pharmaceutical and government clients - a one-stop shop built through five acquisitions and two decades of domain expertise.
- Bought, not just built - five global acquisitions between 2007 and 2019 stitched together capabilities that would have taken decades to develop organically, including over 30 years of accumulated pharmacovigilance experience and a clinical-trial network spanning North America, Europe, Asia, and South America.
- Paid by the hour, the unit, or the milestone - revenue came from a mix of models: clinical-trial management was billed on percentage-of-completion, laboratory services on a fee-for-service basis, regulatory work on time-and-materials or fixed-price contracts, and software licenses upfront at delivery. The company also exploited global cost arbitrage by executing work in lower-cost geographies while billing clients primarily in the United States, which accounted for 68% of revenue in FY21.
2. AI-powered digital health and longevity platforms: a new bet on preventive care
After exiting the CRO business entirely, the company is constructing an asset-light ecosystem of AI-driven apps, smart diagnostic kiosks, and longevity products aimed at India’s consumer and enterprise health market.
- A platform for personalized prevention - the company launched “Take.Health,” an AI-driven digital health platform that analyzes lab reports, builds a dynamic health dashboard, flags predictive risks, and offers condition-specific tracking for areas like diabetes and sleep. It is designed for both individual consumers and workplace wellness programs, with a subscription-based revenue model.
- Smart kiosks for rapid screening - plans for the “One Minute Clinic” involve importing fully integrated smart health units from China that can perform AI-assisted measurement of vital parameters, generate instant digital health reports, and connect users to teleconsultation and diagnostic follow-ups. The goal is self-service preventive screening outside traditional clinic settings.
- A healthcare AI marketplace - a separate Unified AI Platform is being developed as a digital infrastructure layer for hospitals, diagnostic labs, and clinics, offering AI modules for pathology automation, clinical decision support, hospital workflow automation, and clinical trial optimization. The company has integrated AI capabilities from Anthropic’s Claude to strengthen these platforms.
- Longevity sciences and an innovation fund - the company announced an entry into the anti-ageing market with plans for science-backed nutraceuticals, biohacking products, and digital tools for tracking metabolic health and biological aging. It also created an Innovation Fund with an initial corpus of Rs. 50 million to invest in early-stage startups working on AI diagnostics, genomics, cellular health, and digital health infrastructure.
Group structure and partners
A publicly listed shell with a concentrated promoter holding is rebuilding through new subsidiaries and technology partnerships after a cascade of enforced asset sales.
- Stripped of its operating engines - the company’s main subsidiary, TAKE Solutions Global Holdings Pte Ltd, which accounted for 76% of consolidated revenue and 88% of assets, was sold by receivers to H.I.G. Capital in May 2022 for USD 80 million following a loan default. The remaining CRO subsidiary, Ecron Acunova Limited, which contributed 97% of FY24 revenue, was divested to the same buyer in November 2024 for USD 6.50 million.
- A lean structure for a new start - by March 2025, the company had just two full-time employees and two subsidiaries: an ESOP trust and Navitas LLP. It subsequently incorporated TAKE VENTURES PRIVATE LIMITED in March 2026 to house IT and software development activities, and its board approved the disinvestment of its dormant US subsidiary.
- New partnerships for a new thesis - the company’s digital health strategy leans on technology alliances, including the integration of AI capabilities from Anthropic’s Claude, and the Board has amended its charter to permit activities across healthcare technology, diagnostics, pharmaceuticals, and biotechnology as it seeks non-cash business partnerships and acquisitions.